Is Astellas Pharma Inc. (ALPMY) a Buy, Sell, or Hold?
Astellas Pharma Inc.
OTC:ALPMY
$13.14 USD
-$0.08 (-0.61%)
- Volume
- 21.92K
- Average Volume
- 190.76K
- Market Capitalization
- $23.54B
- P/E Ratio
- 13.20
- Dividend Yield
- 3.63%
- Price Target
- Year High
- $17.35
- Year Low
- $9.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.47
- Current Ratio
- $1.17
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Naoki Okamura |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | ALPMY |
| CUSIP | 04623U102 |
| CIK | None |
| Web | https://www.astellas.com |
| Phone | 81 3 3244 3000 |
| Currency | USD |
| Employees | 14099 |
| Country | JP |
Liquidity
| Debt-to-Equity Ratio | 0.31 |
| Payout Ratio | 0.47 |
| Current Ratio | 1.17 |
| Quick Ratio | 0.90 |
| Cash Ratio | 0.23 |
Sales & Book Value
| Annual Sales | $2.27T |
| Price / Sales | 1.80 |
| Cash Flow | 283.18 |
| Price / Cash Flow | 7.57 |
| Price / Book | 2.11 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $172.56 |
| Trailing P/E Ratio | 13.20 |
| PEG Ratio | 0.03 |
| P/E Growth | 0.03 |
| Net Income | $309.12B |
| Net Margin | 13.63% |
| Pretax Margin | 17.60% |
| Return on Equity | 17.44% |
| Return on Assets | 8.17% |
Financials Score
| AltmanZ Score | 2.77 |
| Piotroski Score | 8.00 |
| Working Capital | 204.4B |
| Total Assets | 3.58T |
| Ebit | 445.01B |
| Market Cap | 3.8T |
| Total Liabilities | 1.74T |
Poll Results
About Astellas Pharma Inc. (OTC:ALPMY) Stock
Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide. The company's diverse pipeline and marketed portfolio address critical unmet medical needs across various therapeutic areas. In oncology, Astellas offers XTANDI, an androgen receptor signaling inhibitor used in prostate cancer; XOSPATA, a FLT3 inhibitor designed for adults with relapsed or refractory acute myeloid leukemia characterized by a FLT3 mutation; and PADCEV, a treatment option for patients with locally advanced or metastatic urothelial cancer. For urological conditions, key offerings include Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist managing urgency, urinary f ... requency, and urge urinary incontinence, alongside Vesicare for overactive bladder and mirabegron specifically for pediatric neurogenic detrusor overactivity. Other urology-related products include Eligard for prostate cancer and Harnal/Omnic for benign prostatic hyperplasia. Beyond oncology and urology, the company provides Evrenzo, an oral medication for anemia linked to chronic kidney disease, and the immunosuppressant family Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ rejection in transplant recipients. Funguard/MYCAMINE serves as an antifungal agent. Astellas actively engages in numerous strategic collaborations to expand its innovation pipeline. These include clinical trial partnerships with Merck & Co., Inc. and CytomX Therapeutics, Inc., as well as an innovative agreement with BANDAI NAMCO Entertainment Inc. to develop a smartphone-based exercise support application. Further alliances encompass a strategic research partnership with Harvard University focused on therapeutics and technologies, a research collaboration with Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies using its Antibody Warhead Enabling platform, and an agreement with Zenith Epigenetics Ltd. for the evaluation of ZEN-3694. The company also maintains a collaboration with Cytokinetics, Incorporated, and has forged a strategic partnership and license agreement with Minovia Therapeutics Ltd. to develop cell therapy programs addressing diseases stemming from mitochondrial dysfunction. Founded in 1923, Astellas Pharma Inc. maintains its corporate headquarters in Tokyo, Japan.
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
2026-06-22 10:41:24
Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
Is Astellas Pharma (ALPMY) Stock Undervalued Right Now?
2026-06-22 10:41:23
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Astellas Pharma (ALPMY) a Great Value Stock Right Now?
2026-06-05 10:40:44
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
2026-06-05 10:40:43
Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-06-04 12:51:54
Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Astellas Targets ¥4.3 Trillion Profit Push As Xtandi Pressure Builds
2026-05-26 13:18:00
Astellas Pharma (ALPMY) is trying to give investors a new growth story as Xtandi, its blockbuster prostate cancer drug co-marketed with Pfizer (PFE), moves clos
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
2026-05-25 13:26:05
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
2026-05-13 10:40:33
Here is how Astellas Pharma Inc. (ALPMY) and BillionToOne (BLLN) have performed compared to their sector so far this year.
Frequently Asked Questions
-
What is the current Astellas Pharma Inc. (ALPMY) stock price?
-
Astellas Pharma Inc.(OTC:ALPMY) stock price is $13.14 in the last trading session. During the trading session, ALPMY stock reached the peak price of $17.35 while $9.46 was the lowest point it dropped to. The percentage change in ALPMY stock occurred in the recent session was --0.61% while the dollar amount for the price change in ALPMY stock was -$0.08.
-
ALPMY's industry and sector of operation?
-
The OTC listed ALPMY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of ALPMY?
-
Nori Kuwahara | Senior Vice President of Planning & Administration
Atsushi Kitamura | Chief Financial Officer
Naoki Okamura | President, CEO & Representative Director
Jun Kono | Senior Executive Officer & Head of Japan Commercial
Katsuyoshi Sugita | Executive Vice President, Chief People Officer & Representative Director -
How many employees does ALPMY have?
-
Number of ALPMY employees currently stands at 14099. ALPMY operates from 2-5-1, Nihonbashi-Honcho, Tokyo, TY 103-8411, JP.
-
Link for ALPMY official website?
-
Official Website of ALPMY is: https://www.astellas.com
-
How do I contact ALPMY?
-
ALPMY could be contacted at phone #81 3 3244 3000 and can also be accessed through its website. ALPMY operates from 2-5-1, Nihonbashi-Honcho, Tokyo, TY 103-8411, JP.
-
How many shares of ALPMY are traded daily?
-
The average number of ALPMY shares traded daily for last 3 months was 190.76K.
-
What is the market cap of ALPMY currently?
-
The market value of ALPMY currently stands at $23.54B with its latest stock price at $13.14